

***Fiscal Year 2021 Kidney Cancer Research Program (KCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Academy of Kidney Cancer Investigators – Early-Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-KCRP-AKCIECIA</p>	<p>Must be within 3 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline.</p> <p><i>A letter attesting to eligibility is required.</i></p>	<ul style="list-style-type: none"> • Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty. • Early-Career Investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • A Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding is required. • The Designated Mentor is not required to be at the same institution as the Early-Career Investigator. • <i>Preliminary data are required.</i> • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • Maximum funding of \$725,000 for direct costs (plus indirect costs). • Maximum period of performance is 4 years. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): September 14, 2021 5:00 p.m. Eastern time</p> <p>Application: October 5, 2021 11:59 p.m. Eastern time</p>
<p>Clinical Research Nurse Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-KCRP-CRNDA</p>	<p>The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor (or equivalent) with an M.D. and/or M.D./Ph.D. degree (or equivalent).</p> <p>The Partnering PI must be a <i>clinical research nurse coordinator</i> with at least 2 years of oncology or cancer clinical trial research nurse experience, and have a Registered Nurse license and/or a Bachelor’s, Master’s, or Doctoral degree in nursing.</p>	<ul style="list-style-type: none"> • Supports partnerships between a clinician and a clinical research nurse coordinator (or equivalent). • Supports kidney cancer research and the career development of kidney cancer clinical trial research nurses. • <i>Clinical trials are not allowed; correlative studies to clinical trials are allowed.</i> 	<ul style="list-style-type: none"> • Maximum funding of \$300,000 for direct costs (plus indirect costs). • Maximum period of performance is 2 years. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): September 14, 2021 5:00 p.m. Eastern time</p> <p>Application: October 5, 2021 11:59 p.m. Eastern time</p>

***Fiscal Year 2021 Kidney Cancer Research Program (KCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-KCRP-CTA</p>	<p>Independent investigators at all levels.</p>	<ul style="list-style-type: none"> • Supports projects ranging from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. • Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. • Investigational New Drug (IND) or Investigational Device Exemption (IDE) application, if applicable, must be submitted to the U.S. Department of Food and Drug Administration (FDA) by the time of application submission. • Documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study must be provided. • Clinical trials are expected to begin no later than 12 months after the award date, or 18 months after the award date for FDA-regulated studies. 	<ul style="list-style-type: none"> • Maximum funding of \$2,000,000 for direct costs (plus indirect costs). • Maximum period of performance is 4 years. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): September 14, 2021 5:00 p.m. Eastern Time</p> <p>Application: October 5, 2021 11:59 p.m. Eastern Time</p>
<p>Concept Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-KCRP-CA</p>	<p>All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.</p>	<ul style="list-style-type: none"> • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. • Emphasis on innovation. • <i>Preliminary data are not allowed.</i> • <i>Clinical trials are not allowed.</i> • <i>Blinded review.</i> 	<ul style="list-style-type: none"> • Maximum of \$75,000 for direct costs (plus indirect costs). • Maximum period of performance is 1 year. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 22, 2021 5:00 p.m. Eastern time</p> <p>Application: July 13, 2021 11:59 p.m. Eastern time</p>

***Fiscal Year 2021 Kidney Cancer Research Program (KCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-KCRP-IDA</p>	<p>Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or</p> <p>Early-Career Investigators: Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission.</p>	<ul style="list-style-type: none"> • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer. • Innovation and Impact are the most important review criteria. • Different funding options, based on the scope of the proposed research, are available with compelling justification. • <i>Preliminary data are required.</i> • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • Maximum funding of \$600,000 in direct costs (plus indirect costs). • Period of performance not to exceed 3 years. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. <p>Early Detection Studies Option:</p> <ul style="list-style-type: none"> • Maximum funding of \$650,000 in direct costs (plus indirect costs). • Period of performance not to exceed 3 years. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. <p>Population Science and Prevention Studies Option:</p> <ul style="list-style-type: none"> • Maximum funding of \$2 million in direct costs (plus indirect costs). • Period of performance not to exceed 4 years. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Preproposal): June 15, 2021 5:00 p.m. Eastern time</p> <p>Invitation to Submit an Application: August 06, 2021</p> <p>Application: October 5, 2021 11:59 p.m. ET</p>

***Fiscal Year 2021 Kidney Cancer Research Program (KCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Postdoctoral and Clinical Fellowship Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-KCRP-PCFA</p>	<p>Must have completed requirements for a Ph.D. and/or M.D.</p> <p>Must be in the laboratory or clinical setting where proposed research will be performed.</p> <p>Must have no more than 4 years of postdoctoral and/or mentored clinical research experience.</p> <p><i>Investigators in non-postdoctoral and/or clinical fellow positions are not eligible.</i></p>	<ul style="list-style-type: none"> • Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers. • A designated mentor who is an experienced kidney cancer researcher is required. • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • Maximum funding of \$195,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): June 22, 2021 5:00 p.m. Eastern time</p> <p>Application: July 13, 2021 11:59 p.m. Eastern time</p>
<p>Translational Research Partnership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-KCRP-TRPA</p>	<p>The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor or equivalent.</p> <p>The Partnering PI must be at or above the level of Assistant Professor or equivalent.</p> <p><i>Postdoctoral fellows are not eligible to be Partnering PIs.</i></p>	<ul style="list-style-type: none"> • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications. • Supports translational correlative studies. • <i>Preliminary data are required.</i> • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • Maximum funding of \$750,000 for direct costs (plus indirect costs). • Maximum period of performance is 3 years. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	<p>Pre-Application (Preproposal): June 15, 2021 5:00 p.m. Eastern time</p> <p>Invitation to Submit an Application: August 06, 2021</p> <p>Application: October 5, 2021 11:59 p.m. ET</p>